4-PrO-DMT

active cardiovascular disease, uncontrolled hypertension, cardiac arrhythmia

Psilocin-class psychedelics produce transient dose-dependent increases in systolic blood pressure and heart rate. For 4-PrO-DMT specifically, the atypically potent 5-HT2B binding (Ki = 17 nM) introduces additional uncertainty, as chronic 5-HT2B agonism is the established mechanism for cardiac valvulopathy associated with fenfluramine and ergotamine. Three mitigating factors apply: rapid prodrug conversion to psilocin (lower 5-HT2B affinity), typically intermittent psychedelic use patterns, and relative cardiovascular safety observed in clinical psilocybin studies. Whether the intact prodrug engages cardiac 5-HT2B before hydrolysis remains unresolved.

current lithium use

Concurrent lithium use with classic serotonergic psychedelics carries an alarmingly high seizure rate (47% of 62 analyzed reports). The mechanism remains unidentified. This is classified as an absolute contraindication for all psilocin-class compounds, including 4-PrO-DMT. Lamotrigine does not carry this risk (0/34 reports involved seizures), suggesting the interaction is lithium-specific rather than a general mood-stabilizer effect.

schizophrenia, schizoaffective disorder, bipolar I disorder, family history of psychosis

Serotonergic psychedelics potently activate 5-HT2A receptors on cortical pyramidal neurons, disrupting thalamocortical gating and increasing neural entropy. In individuals with latent or active psychotic vulnerability, this can precipitate prolonged psychotic episodes, mania, or exacerbation of existing symptoms. Risk extends to first-degree family history of these conditions. This is a class-level contraindication established for the psilocin/psilocybin pharmacological class and applied to 4-PrO-DMT by structural analogy as a psilocin prodrug.

borderline personality disorder

Emotional lability — a core feature of borderline personality disorder — may be intensified by serotonergic psychedelics via 5-HT2A-mediated emotional enhancement. This could exacerbate affective instability, interpersonal reactivity, and impulsive behavior during the acute experience. This is a class-level relative contraindication applied by structural analogy.

pregnancy, breastfeeding

No published safety data exist for 4-PrO-DMT, psilocin, or psilocybin during pregnancy or breastfeeding. The serotonin system plays critical roles in fetal neurodevelopment, and 5-HT2A agonism carries theoretical risk of developmental disruption. Classified as an absolute contraindication based on absence of safety data.

current MAOI use, tranylcypromine, phenelzine, isocarboxazid, selegiline (high-dose)

Monoamine oxidase inhibitors block the MAO-A-mediated deamination pathway for psilocin (the active metabolite of 4-PrO-DMT), causing serotonin accumulation and risk of serotonin toxicity. A case report documented hypertensive emergency and myocardial infarction in a patient on tranylcypromine and dextroamphetamine who consumed psilocybin mushrooms. For synthetic 4-PrO-DMT (which lacks mushroom-derived phenylethylamines), the primary MAOI risk is serotonin toxicity via impaired 5-HT metabolism. This constitutes both a pharmacokinetic amplifier and a pharmacodynamic hazard.

current SSRI use

Selective serotonin reuptake inhibitors may blunt the psychedelic effect of 4-PrO-DMT through pharmacodynamic competition at 5-HT2A receptors (increased endogenous serotonin competes with psilocin for receptor binding). The clinical concern is compensatory dose escalation — users who find effects blunted may take higher doses, increasing the risk of adverse effects if SSRI is discontinued or the interaction is variable. This is a class-level pharmacodynamic interaction for all psilocin-class compounds.

current TCA use

Tricyclic antidepressants may enhance the intensity of psilocin-mediated psychedelic effects through serotonin and norepinephrine reuptake inhibition. This pharmacodynamic interaction could result in unexpectedly intense experiences at standard doses. Dose adjustment or avoidance should be considered under medical guidance.